Better Health for All

RAPT Therapeutics is a clinical-stage biopharmaceutical company entirely focused on discovering, developing, and commercializing novel therapies for inflammatory and immunologic diseases, including food allergies, eczema, asthma, and chronic spontaneous urticaria.

Its investigational drugs, such as ozureprubart, RPT193, and zelnecirnon, aim to provide substantial health benefits, potentially offering more convenient or broader treatment options than existing therapies. The company's entire business model is dedicated to health improvement, with all products in development targeting significant health challenges. The company offers free participation in its clinical trials, and some travel costs may be reimbursed, indicating a commitment to accessibility. Trials for ozureprubart include participants aged 12-55 with food allergies, and trials for RPT193 are open to adults aged 18-75 with moderate to severe eczema, demonstrating efforts to reach specific patient populations. The company consistently discloses risk factors in SEC filings and conducts randomized, double-blind, placebo-controlled trials, indicating a commitment to transparency and ethical research. However, the FDA placed a clinical hold on zelnecirnon trials due to one case of liver failure in a participant, which was considered possibly related to the treatment, though no other liver toxicity was reported across approximately 350 participants for that drug. Other investigational drugs, RPT904 and RPT193, have been well tolerated in trials with no serious adverse events reported.

Fair Money & Economic Opportunity

RAPT Therapeutics, Inc. is a pre-revenue biotechnology company focused on developing small molecule therapies for inflammatory and immuno-oncology conditions.

The company's business model does not involve offering lending, deposit services, or any other financial products to consumers. Therefore, all KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fees, inclusion initiatives, data accessibility, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion, and product simplicity, are not applicable to its operations.

Fair Pay & Worker Respect

Women at RAPT Therapeutics are paid, on average, 101% of male salaries for jobs at the same level, and the company conducts an annual pay equity analysis.

Employee reviews indicate that 66% of employees would recommend working at RAPT Therapeutics to a friend. In July 2024, the company reduced its workforce by approximately 40%, impacting 47 people, and as of March 31, 2025, had 67 full-time employees.

Honest & Fair Business

The company has a Whistleblower Policy for Accounting and Auditing Matters, and procedures for employees to submit concerns anonymously, with employees expected to report suspected violations without fear of retaliation.

However, there is no evidence of independent investigation processes. RAPT Therapeutics has had zero financial restatements in the past five years. The board of directors has determined that 6 out of 7 directors are independent, with the CEO being the only non-independent director, resulting in approximately 85.7% independent directors. The company's Code of Business Conduct and Ethics mandates compliance with the FCPA and other anti-corruption laws, and includes training for new employees and annual refresher sessions, covering all countries of operation. The company relies on third-party clinical investigators, contract research organizations, and contract development and manufacturing organizations for preclinical studies, clinical trials, and product materials, but the extent of independent verification of ethical claims is not specified.

Kind to Animals

The provided articles, primarily financial reports, do not contain specific, concrete data points for any of the 'Kind to Animals' KPIs. While one article mentions that certain laws and regulations require the company to test drug candidates on animals,

there is no explicit formal animal testing policy or details on the company's stance, reduction efforts, or use of alternatives. Therefore, all KPIs related to animal welfare must be omitted due to a lack of direct evidence.

No War, No Weapons

RAPT Therapeutics, Inc. is a clinical-stage immunology-based biopharmaceutical company focused on developing therapies for inflammatory diseases.

The provided articles, including corporate presentations, financial reports, and news about an acquisition, do not contain any information or specific data points related to arms manufacturing, military contracts, dual-use technology, sales to embargoed regimes, peacebuilding investments, or any other metrics relevant to the 'No War, No Weapons' ethical value. Therefore, no KPIs can be scored based on the evidence provided.

Planet-Friendly Business

No specific, quantitative data points were found across the provided articles for any of the 'Planet-Friendly Business' KPIs.

The articles, including SEC filings and third-party ESG summaries, consistently state 'No data found,' 'No information provided,' or 'No specific sustainability data' for metrics such as emissions, renewable energy use, water consumption, waste diversion, or environmental compliance violations. Policy statements regarding environmental responsibility were noted, but these do not constitute measurable evidence for scoring against the quantitative thresholds of the rubric.

Respect for Cultures & Communities

The provided articles do not contain any specific, concrete data points or metrics related to RAPT Therapeutics' respect for cultures and communities. Information regarding formal partnerships with indigenous or local community groups, revenue reinvested in local communities, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms, FPIC participation, community governance inclusion, cultural preservation investment, local procurement, indigenous suppliers, cultural site protection, social license to operate, charitable giving to cultural organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training is absent.

The articles primarily focus on financial announcements, board appointments, clinical trials, and general ESG risk scores without providing details relevant to the specified KPIs. The RAPT Foundation, mentioned in one article, is a separate 501(c)(3) organization and its activities are not directly attributable to RAPT Therapeutics' performance on these specific metrics.

Safe & Smart Tech

The company allows users to request the removal of Personally Identifiable Information by written request.

However, it explicitly states that it cannot ensure the permanent removal of this information. No further details on user control over data or privacy settings are provided.

Zero Waste & Sustainable Products

No specific, quantitative evidence was found in the provided articles regarding RAPT Therapeutics' performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.

The articles provided general ESG scores but lacked the granular data required for these specific metrics.